The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers

por Atherly, A J, Camidge, D R
Publicado 2012

Factors affecting the mesothelioma detection rate within national and international epidemiological studies: insights from Scottish linked cancer registry-mortality data

por Camidge, D R, Stockton, D L, Bain, M
Publicado 2006

The impact of socioeconomic status on access to cancer clinical trials

por Sharrocks, K, Spicer, J, Camidge, D R, Papa, S
Publicado 2014

Economic evaluation of fulvestrant as an extra step in the treatment sequence for ER-positive advanced breast cancer

por Cameron, D A, Camidge, D R, Oyee, J, Hirsch, M
Publicado 2008

Hospital admissions and deaths relating to deliberate self-harm and accidents within 5 years of a cancer diagnosis: a national study in Scotland, UK

por Camidge, D R, Stockton, D L, Frame, S, Wood, R, Bain, M, Bateman, D N
Publicado 2007

Assessing proliferation, cell-cycle arrest and apoptotic end points in human buccal punch biopsies for use as pharmacodynamic biomarkers in drug development

por Camidge, D R, Pemberton, M N, Growcott, J W, Johnstone, D, Laud, P J, Foster, J R, Randall, K J, Hughes, A M
Publicado 2005

Evolution of MET and NRAS gene amplification as acquired resistance mechanisms in EGFR mutant NSCLC

por Peters, T. L., Patil, T., Le, A. T., Davies, K. D., Brzeskiewicz, P. M., Nijmeh, H., Bao, L., Camidge, D. R., Aisner, D. L., Doebele, R. C.
Publicado 2021

Plucked human hair as a tissue in which to assess pharmacodynamic end points during drug development studies

por Camidge, D R, Randall, K R, Foster, J R, Sadler, C J, Wright, J A, Soames, A R, Laud, P J, Smith, P D, Hughes, A M
Publicado 2005

Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study

por Gadgeel, S, Peters, S, Mok, T, Shaw, A T, Kim, D W, Ou, S I, Pérol, M, Wrona, A, Novello, S, Rosell, R, Zeaiter, A, Liu, T, Nüesch, E, Balas, B, Camidge, D R
Publicado 2018

A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small c...

por Chow, L. Q. M., Blais, N., Jonker, D. J., Laurie, S. A., Diab, S. G., Canil, C., McWilliam, M., Thall, A., Ruiz-Garcia, A., Zhang, K., Tye, L., Chao, R. C., Camidge, D. R.
Publicado 2011

Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001

por Shaw, A T, Riely, G J, Bang, Y -J, Kim, D -W, Camidge, D R, Solomon, B J, Varella-Garcia, M, Iafrate, A J, Shapiro, G I, Usari, T, Wang, S C, Wilner, K D, Clark, J W, Ou, S -H I
Publicado 2019

Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma

por Krug, A K, Enderle, D, Karlovich, C, Priewasser, T, Bentink, S, Spiel, A, Brinkmann, K, Emenegger, J, Grimm, D G, Castellanos-Rizaldos, E, Goldman, J W, Sequist, L V, Soria, J -C, Camidge, D R, Gadgeel, S M, Wakelee, H A, Raponi, M, Noerholm, M, Skog, J
Publicado 2018

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

por Mazieres, J., Drilon, A., Lusque, A., Mhanna, L., Cortot, A.B., Mezquita, L., Thai, A.A., Mascaux, C., Couraud, S., Veillon, R., Van den Heuvel, M., Neal, J., Peled, N., Früh, M., Ng, T.L., Gounant, V., Popat, S., Diebold, J., Sabari, J., Zhu, V.W., Rothschild, S.I., Bironzo, P., Martinez-Marti, A., Curioni-Fontecedro, A., Rosell, R., Lattuca-Truc, M., Wiesweg, M., Besse, B., Solomon, B., Barlesi, F., Schouten, R.D., Wakelee, H., Camidge, D.R., Zalcman, G., Novello, S., Ou, S.I., Milia, J., Gautschi, O.
Publicado 2019